HIV/HBV/HCV検査キットの世界市場-2022-2029

市場概要

HIV/HBV/HCV検査キットの世界市場規模は、予測期間（2022-2029年）にCAGR6.8%で成長すると予測されています。

HIV/HBV/HCV検査は、ヒト血清、血漿、全血中のB型肝炎表面抗原（HBsAg）およびHIV-1、HIV-2、Treponema pallidum（Tp）、HCVに対する抗体の定性検出と鑑別のための検査であり、HIV/HBV/HCV検査は、ヒト血清、血漿、全血中のHV-2、TpおよびHCVに対する抗体の定性検出と鑑別のための検査です。

市場力学

HIV/HBV/HCV迅速検査キットにおける技術革新が市場成長の原動力になると予想されます。

共同感染率が高いサハラ以南のアフリカでは、HIV、HBV、HCVの感染による負担が不均衡に高い状態が続いています。HIV、HBV、HCVの血清学的検査のための高い分析性能のマルチプレックス高速診断法は、スクリーニングのカスケードを強化し、より費用対効果の高いケアへのつながりをもたらす可能性があります。このような検査方法は、手の届かない高リスクの人々にとって特に有用であり、また、自己検査が公衆衛生に与える影響を高める可能性があります。例えば、プロトタイプの指刺し全血トリプレックスHIV/HCV/HBsAg自己検査は、HIV、HBV、HCV感染を特定するための迅速、安価、ツールフリーで使いやすい方法を提供する可能性があります。特に、サハラ以南のアフリカで密接に関連する3つの風土病のスクリーニングを改善するのに適している可能性があります。これらのオプションは、スクリーニングの努力を高め、診断されていないHIV、HBV、またはHCV感染によって引き起こされる病気の将来のコストを下げ、これらの感染症を治療し、HCV感染を根絶する努力を支援する可能性があります。このように、上記の要因から、予測期間中に市場が牽引されることが期待されます。

慢性B型肝炎およびC型肝炎に関する人々の知識と意識の欠如が、市場成長の妨げになると予想されます。

国立医学図書館によると、ヘルスケアプロバイダー、社会サービスプロバイダー、および一般市民は、B型およびC型肝炎の感染について認識していないとのことです。米国における慢性ウイルス性肝炎の流行状況や、慢性B型肝炎およびC型肝炎のスクリーニングや医療管理の適切な方法と対象者についての認識不足が、感染の継続、ワクチン接種などの予防機会の喪失、早期診断と医療の機会の喪失、感染者の健康状態の悪化につながる可能性が高いのです。したがって、上記の要因から、予測期間中に市場が阻害されることが予想されます。

産業分析

HIV/HBV/HCV検査キット市場は、サプライチェーン分析、価格分析など、様々な産業要因に基づく市場の詳細な分析を提供します。

COVID-19の影響分析

COVID-19のパンデミックは、市場に中程度の影響を及ぼしています。パンデミックはヘルスケアシステムを混乱させ、基本的な臨床ケア、HIV/HBV/HCV検査、治療の提供をより困難なものにしています。その結果、パンデミック時にHIV、HBV、HCVと診断されていなかった人々が、その後、より進行した病気で発見されることにより、罹患率と死亡率の増加がもたらされる可能性があります。また、世界保健機関（WHO）によると、2020年には、B型肝炎の検査で10カ国、C型肝炎の治療開始で6カ国、家族計画で5カ国が混乱したと報告されています。また、COVID-19独自のパンデミック緩和策の一環として、2020年、CDCは日常的な臨床訪問の延期と必要でない業務の遅延に関するガイドラインを発表しました。このアドバイスにより、患者は不必要な対面診療を避け、遠隔医療、患者ポータル、電話、電子メールなどで医療従事者とコミュニケーションをとることができます。このように、COVID-19のパンデミックは市場に影響を及ぼしています。しかし、この状況は予測期間中に徐々に改善されると予想されます。

目次

第1章 調査手法と調査範囲

• 調査手法
• 調査目的および調査範囲

第2章 市場の定義と概要

第3章 エグゼクティブサマリー

第4章 市場力学

• 市場影響要因
  • 促進要因
    • HIV/HBV/HCV迅速検査キットにおける技術革新が市場成長を促進すると予想されます。
  • 抑制要因
    • 慢性B型肝炎やC型肝炎に関する人々の知識と意識の欠如が、市場成長の妨げになると予想されます。
  • 機会
  • 影響分析

第5章 産業分析

• サプライチェーン分析
• 価格設定分析

第6章 COVID-19の分析

• COVID-19の市場分析
  • COVID-19以前の市場シナリオ
  • COVID-19の現在の市場シナリオ
  • COVID-19の後、または将来のシナリオ
• COVID-19の中での価格ダイナミクス
• 需要-供給スペクトラム
• パンデミック時の市場に関連する政府の取り組み
• メーカーの戦略的な取り組み
• まとめ

第7章 検査タイプ別

• ラピッドテストキット
• アッセイベース検査キット

第8章 サンプルタイプ別

• 唾液
• 血液
• 尿

第9章 エンドユーザー別

• 病院
• 診断研究所
• 診療所
• 政府機関、NGO
• その他

第10章 地域別

• 北米
  • 米国
  • カナダ
  • メキシコ
• 欧州
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン
  • その他欧州
• 南米
  • ブラジル
  • アルゼンチン
  • その他の南米地域
• アジア太平洋地域
  • 中国
  • インド
  • 日本
  • オーストラリア
  • その他アジア太平洋地域
• 中東・アフリカ地域

第11章 競合情勢

• 主な展開と戦略
• 企業シェア分析
• 注目の主要企業リスト

第12章 企業プロファイル

• F. Hoffmann-La Roche Ltd
  • 企業概要
  • 製品ポートフォリオと内容
  • 主なハイライト
  • 財務概要
• Bio-Rad Laboratories Inc.
• Abbott Laboratories
• Meridian Bioscience, Inc.
• Biopanda Reagents Ltd
• Nanjing Synthgene Medical Technology Co., Ltd.
• AccuBioTech Co., Ltd.
• BioMerieux SA
• QIAGEN
• Hologic Inc
• Creative Diagnostics

第13章 HIV/HBV/HCV検査キットの世界市場-DataM

Market Overview

The global HIV/HBV/HCV test kits market size was valued US$ YY million in 2021 and is expected to reach US$ XX million by 2029, growing at a CAGR of 6.8 % during the forecast period (2022-2029).

HIV/HBV/HCV test is a test of qualitative detection and differentiation of hepatitis B surface antigen (HBsAg) and antibodies to HIV-1, HIV-2, Treponema pallidum (Tp), and HCV in human serum, plasma, or whole blood.

Market Dynamics

Innovations in the HIV/HBV/HCV rapid test kits is expected to drive market growth.

In sub-Saharan Africa, where co-infection rates are high, the burden of HIV, HBV, and HCV infections continues to be disproportionately high. High analytical performance multiplex fast diagnostic procedures for HIV, HBV, and HCV serological testing may enhance the cascade of screening and result in more cost-effective linkage to care. Such a testing approach may be especially helpful for high-risk populations challenging to reach and may also boost the impact of self-testing on public health. For instance, The prototype finger-stick whole-blood Triplex HIV/HCV/HBsAg self-test may offer a quick, affordable, tool-free, and user-friendly method for identifying HIV, HBV, and HCV infections. It might be especially appropriate for improving the screening of three endemic viral illnesses closely related in sub-Saharan Africa. These options could increase screening efforts, lowering the future cost of diseases caused by undiagnosed HIV, HBV, or HCV infections and assisting with efforts to treat these infections and potentially eradicate HCV infection. Thus, from the above factors, the market is expected to drive in the forecast period.

Lack of knowledge and awareness about chronic hepatitis B and hepatitis C among people is expected to hamper the market growth.

According to the National Library of Medicine, healthcare providers, social-service providers, and the general public are unaware of hepatitis b&c infections. Lack of awareness about the prevalence of chronic viral hepatitis in the U.S., as well as the appropriate methods and target populations for screening and medical management of chronic hepatitis B and hepatitis C, most likely contributes to ongoing transmission; missed opportunities for prevention, including vaccination; missed opportunities for early diagnosis and medical care; and poor health outcomes in infected people. Thus, from the above-mentioned factors, the market is expected to get hampered in the forecast period.

Industry Analysis

The HIV/HBV/HCV test kits market provides in-depth analysis of the market based on various industry factors such as supply chain analysis, pricing analysis etc.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted the market. The pandemic has disrupted healthcare systems, making it more difficult to provide basic clinical care, HIV/HBV/HCV testing, and treatment. As a result, increased morbidity and mortality rates may result from those who had undiagnosed HIV, HBV, and HCV during the pandemic subsequently being found to have the disease in more advanced stages. Besides, according to the World Health Organisation, in 2020, 10 countries reported disruption in Hepatitis B testing, 6 in Hepatitis C Treatment initiation, and 5 in Family Planning. In addition, as part of the original COVID-19 pandemic mitigation initiatives, in 2020, the CDC published guidelines on deferring routine clinical visits and delaying non-essential operations. With this advice, patients avoid making unnecessary in-person visits and communicate with their healthcare practitioner via telemedicine, patient portals, phone, and email. Thus, the COVID-19 pandemic has affected the market. However, the situation is expected to improve gradually in the forecast period.

Segment Analysis

Assay Based Test Kits segment is expected to hold the largest market share in HIV/HBV/HCV test kits market

The assay-based test kits segment accounted for the largest market share in 2021. The segment benefits because these are the first line of patient tests. Moreover, healthcare professionals and patients in most developing regions rely on assay-based testing results. For instance, The HCV Ag assay has the advantages of being an immunoassay, not requiring the same time-consuming and costly sample processing as molecular diagnostics, and confirming current infection. Moreover, there have been innovations in assay-based test kits. For instance, One point-of-care test that uses the GeneXpert System is the Xpert HCV Viral Load Fingerstick Test from Cepheid. The finger-stick whole blood capillaries is examined for HCV RNA as part of this point-of-care test (or assay). This type of HCV testing involves taking capillary blood from the patient through a finger prick into a collection device called a Minivette, which is then processed in a GeneXpert device at or near the point-of-care testing location.

In addition, most patients with acquired immunodeficiency syndrome (AIDS) and AIDS-related complex (ARC), as well as many asymptomatic people in high-risk groups, have been found to have antibodies to the human immunodeficiency virus (HIV). The existence of these HIV antibodies is frequently checked in human blood and plasma samples using enzyme-linked immunosorbent assays (ELISA). For instance, INNO-LIA HIV I/II Score is a Line Immuno Assay (LIA) that establishes the existence of antibodies against HIV-1, including group O and HIV-2 in human blood or plasma. The HIV I/II Score from INNO-LIA distinguishes between HIV-1 and HIV-2 infections. It is meant to be used in addition to an anti-HIV screening process on reactive specimens. Therefore, it has increased the demand for assay-based test kits. Thus, from the above factors, the market segment is expected to hold the largest market share in the forecast period.

Geographical Analysis

Middle East and Africa region holds the largest market share in the global HIV/HBV/HCV test kits market

In 2021, the Middle East and Africa accounted for the highest revenue share. The increasing prevalence of HIV, innovations in the HIV/HBV/HCV test kits, advancing guidelines for self-testing and well-established infrastructure in the region are some factors the market is expected to boost in the forecast period. For instance, according to the UNAIDS, in 2020, HIV prevalence in Eswatini was 26.8 %. HIV prevalence in Eswatini increased from 22.9 % in 2001 to 26.8 % in 2020, growing at an average annual rate of 0.84%. Moreover, new WHO guidelines strongly advise offering self-testing for the hepatitis C virus (HCV) as an alternate method to HCV testing facilities. On the occasion of the International AIDS Society Conference in 2021, WHO issued the updated guidelines-it is the first for HCV self-testing. The new guidelines highlight important factors that should be taken into account by national programs, service providers, and implementers of HCV testing. These factors for HCV self-testing include developing suitable and context-specific messages, service delivery models, and support tools through community engagement; creating effective pathways for people who self-test to obtain confirmatory testing and treatment or prevention services; educating providers; creating a supportive and enabling policy environment; and using quality-assured products. Besides, WHO has also developed technical specifications for prequalifying HCV self-testing products to ensure quality. Therefore, it has increased the demand for HIV/HBV/HCV test kits. Thus, from the above factors, the Middle East and Africa region is expected to hold the largest market share in the forecast period.

Competitive Landscape

Major key players in the HIV/HBV/HCV test kits market are F. Hoffmann-La Roche Ltd; Bio-Rad Laboratories Inc.; Abbott Laboratories; Meridian Bioscience, Inc.; Biopanda Reagents Ltd; Nanjing Synthgene Medical Technology Co., Ltd.; AccuBioTech Co., Ltd.; BioMerieux SA; QIAGEN; Hologic Inc; and Creative Diagnostics.

F. Hoffmann-La Roche Ltd:

Overview:

Hoffmann-La Roche Ltd is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. It is one of the largest biotech companies, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology, and neuroscience. It is a global leader in in-vitro and tissue-based cancer diagnostics and a frontrunner in diabetes management. Its personalized healthcare strategy aims to provide medicines and diagnostics that enable tangible improvements in patients' health, quality of life and survival. Moreover, Roche Molecular, one of four customer-focused areas of Roche Diagnostics Solutions, develops, manufactures and supplies a wide array of innovative molecular diagnostic products, tests, platforms and technologies used to identify and quantify DNA and RNA from different organisms.

Product Portfolio:

cobas MPX: The cobas MPX Test is a multi-dye, real-time PCR multiplex test for human immunodeficiency virus (HIV), hepatitis C virus (HCV) and hepatitis B virus (HBV) for use on the cobas 6800/8800 Systems. The single assay allows for simultaneous detection of three targets, improving efficiency and accuracy.

The global HIV/HBV/HCV test kits market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Table of Contents

1. Methodology and Scope

• 1.1. Research Methodology
• 1.2. Research Objective and Scope of the Report

2. Market Definition and Overview

3. Executive Summary

4. Market Dynamics

• 4.1. Market Impacting Factors
  • 4.1.1. Drivers
    • 4.1.1.1. Innovations in the HIV/HBV/HCV rapid test kits are expected to drive market growth.
  • 4.1.2. Restraints:
    • 4.1.2.1. Lack of knowledge and awareness about chronic hepatitis B and hepatitis C among people is expected to hamper the market growth.
  • 4.1.3. Opportunity
  • 4.1.4. Impact Analysis

5. Industry Analysis

• 5.1. Supply Chain Analysis
• 5.2. Pricing Analysis

6. COVID-19 Analysis

• 6.1. Analysis of Covid-19 on the Market
  • 6.1.1. Before COVID-19 Market Scenario
  • 6.1.2. Present COVID-19 Market Scenario
  • 6.1.3. After COVID-19 or Future Scenario
• 6.2. Pricing Dynamics Amid Covid-19
• 6.3. Demand-Supply Spectrum
• 6.4. Government Initiatives Related to the Market During Pandemic
• 6.5. Manufacturers Strategic Initiatives
• 6.6. Conclusion

7. By Test Type

• 7.1. Introduction
  • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
  • 7.1.2. Market Attractiveness Index, By Test Type Segment
• 7.2. Rapid Test Kits*
  • 7.2.1. Introduction
  • 7.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 7.3. Assay Based Test Kits

8. By Sample Type

• 8.1. Introduction
  • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Sample Type
  • 8.1.2. Market Attractiveness Index, By Sample Type Segment
• 8.2. Saliva*
  • 8.2.1. Introduction
  • 8.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 8.3. Blood
• 8.4. Urine

9. By End user

• 9.1. Introduction
  • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  • 9.1.2. Market Attractiveness Index, By End user Segment
• 9.2. Hospitals*
  • 9.2.1. Introduction
  • 9.2.2. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029
• 9.3. Diagnostic Laboratories
• 9.4. Clinics
• 9.5. Government Organizations and NGO's
• 9.6. Others

10. By Region

• 10.1. Introduction
  • 10.1.1. Market Size Analysis, US$ Million, 2020-2029 and Y-o-Y Growth Analysis (%), 2021-2029, By Region
  • 10.1.2. Market Attractiveness Index, By Region
• 10.2. North America
  • 10.2.1. Introduction
  • 10.2.2. Key Region-Specific Dynamics
  • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
  • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Sample Type
  • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.2.6.1. U.S.
    • 10.2.6.2. Canada
    • 10.2.6.3. Mexico
• 10.3. Europe
  • 10.3.1. Introduction
  • 10.3.2. Key Region-Specific Dynamics
  • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
  • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Sample Type
  • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  • 10.3.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.3.6.1. Germany
    • 10.3.6.2. U.K.
    • 10.3.6.3. France
    • 10.3.6.4. Italy
    • 10.3.6.5. Spain
    • 10.3.6.6. Rest of Europe
• 10.4. South America
  • 10.4.1. Introduction
  • 10.4.2. Key Region-Specific Dynamics
  • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
  • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Sample Type
  • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.4.6.1. Brazil
    • 10.4.6.2. Argentina
    • 10.4.6.3. Rest of South America
• 10.5. Asia Pacific
  • 10.5.1. Introduction
  • 10.5.2. Key Region-Specific Dynamics
  • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
  • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Sample Type
  • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user
  • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
    • 10.5.6.1. China
    • 10.5.6.2. India
    • 10.5.6.3. Japan
    • 10.5.6.4. Australia
    • 10.5.6.5. Rest of Asia Pacific
• 10.6. Middle East and Africa
  • 10.6.1. Introduction
  • 10.6.2. Key Region-Specific Dynamics
  • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Test Type
  • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Sample Type
  • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By End user

11. Competitive Landscape

• 11.1. Key Developments and Strategies
• 11.2. Company Share Analysis
• 11.3. List of Key Companies to Watch

12. Company Profiles

• 12.1. F. Hoffmann-La Roche Ltd*
  • 12.1.1. Company Overview
  • 12.1.2. Product Portfolio and Description
  • 12.1.3. Key Highlights
  • 12.1.4. Financial Overview
• 12.2. Bio-Rad Laboratories Inc.
• 12.3. Abbott Laboratories
• 12.4. Meridian Bioscience, Inc.
• 12.5. Biopanda Reagents Ltd
• 12.6. Nanjing Synthgene Medical Technology Co., Ltd.
• 12.7. AccuBioTech Co., Ltd.
• 12.8. BioMerieux SA
• 12.9. QIAGEN
• 12.10. Hologic Inc
• 12.11. Creative Diagnostics

LIST NOT EXHAUSTIVE

13. Global HIV/HBV/HCV Test Kits Market - DataM

• 13.1. Appendix
• 13.2. About Us and Applications
• 13.3. Contact Us